Immunis, Inc. filed a Form D with the Securities and Exchange Commission on 2026-06-15.
Immunis, Inc. filed a Form D notice of an exempt securities offering with the SEC on June 15, 2026. The filing reports $11.97M sold. Its industry group is Biotechnology. It names Hans Keirstead (Executive Officer, Director), Takahide Koda (Director), Daniel Kraft (Director) (SEC Form D, June 15, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Immunis, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-06-15 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Immunis, Inc.
Free to see. No signup.
More on the people and the money behind Immunis, Inc., from the filings we hold.
Biotechnology raises by companies based in California, filed in June 2026, largest first.
Get an email when Immunis, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Immunis, Inc. raises, hires or launches. No email unless you switch it on.
Watch Immunis, Inc. →Get the full cited report on Immunis, Inc.
What the filing shows about Immunis, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Immunis, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Immunis, Inc.'s address as 18301 Von Karman Avenue, Suite 350, Irvine, CA 92612.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Immunis, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Immunis, Inc. is a registered filer with the SEC (CIK 2028798) and has filed since 2024-07-01. 2 filings are on record, the latest on 2026-06-15.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Immunis, Inc.'s Form D of 2026-06-15 names Hans Keirstead, Takahide Koda, Daniel Kraft and 1 more as its officers, directors or promoters.
Its new offerings report $27.76M sold across 2 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $11.97M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Hans Keirstead is named as Executive Officer and Director on the Form D that Immunis, Inc. filed with the SEC on 15 June 2026, one of 4 people that filing names.
Takahide Koda is named as Director on the Form D that Immunis, Inc. filed with the SEC on 15 June 2026, one of 4 people that filing names.
Daniel Kraft is named as Director on the Form D that Immunis, Inc. filed with the SEC on 15 June 2026, one of 4 people that filing names.
Gabriel Nistor is named as Executive Officer on the Form D that Immunis, Inc. filed with the SEC on 15 June 2026, one of 4 people that filing names.
4 people named on the filing — 2 holding an executive role and 2 as directors only.
Named as of the 2026-06-15 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Immunis, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Immunis, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Immunis, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Immunis, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Immunis, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Immunis, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Los Angeles
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/immunis-inc-form-d-26000001